(Q46689236)

24 December 2017

title

Direct transition to long-acting risperidone--analysis of long-term efficacy (English)

1 reference

24 December 2017

author name string

Kissling W

1

1 reference

24 December 2017

Heres S

2

1 reference

24 December 2017

Lloyd K

3

1 reference

24 December 2017

Sacchetti E

4

1 reference

24 December 2017

Bouhours P

5

1 reference

24 December 2017

Medori R

6

1 reference

24 December 2017

Llorca PM

7

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

Journal of Psychopharmacology

published in

1 reference

24 December 2017

volume

19

1 reference

24 December 2017

issue

5 Suppl

1 reference

24 December 2017

page(s)

15-21

1 reference

24 December 2017

Relapse in schizophrenia: costs, clinical outcomes and quality of life

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Weight changes during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Risperidone long-acting injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Hospital days in risperidone-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Progress defined--short-term efficacy, long-term effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Non-adherence to antipsychotic medication regimens: associations with resource use and costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Course and long-term treatment of schizophrenic psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Novel antipsychotics in the long-term treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Mechanisms of relapse prevention in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

An economic review of compliance with medication therapy in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056514

21 January 2018

Identifiers

DOI

10.1177/0269881105056514

1 reference

24 December 2017

release_7zibjgd5jbbtxd4n7fvyxyjapa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7zibjgd5jbbtxd4n7fvyxyjapa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

24 December 2017